- Home
- AMC vs ZYME Comparison
AMC vs ZYME Comparison
Compare AMC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- ZYME
- Stock Information
- Founded
- AMC 1920
- ZYME 2003
- Country
- AMC United States
- ZYME United States
- Employees
- AMC N/A
- ZYME N/A
- Industry
- AMC Movies/Entertainment
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- AMC Consumer Discretionary
- ZYME Health Care
- Exchange
- AMC Nasdaq
- ZYME Nasdaq
- Market Cap
- AMC 1.3B
- ZYME 1.2B
- IPO Year
- AMC 2013
- ZYME 2017
- Fundamental
- Price
- AMC $2.59
- ZYME $18.83
- Analyst Decision
- AMC Hold
- ZYME Strong Buy
- Analyst Count
- AMC 7
- ZYME 9
- Target Price
- AMC $3.94
- ZYME $22.88
- AVG Volume (30 Days)
- AMC 27.6M
- ZYME 865.0K
- Earning Date
- AMC 11-05-2025
- ZYME 11-06-2025
- Dividend Yield
- AMC N/A
- ZYME N/A
- EPS Growth
- AMC N/A
- ZYME N/A
- EPS
- AMC N/A
- ZYME N/A
- Revenue
- AMC $4,915,600,000.00
- ZYME $122,867,000.00
- Revenue This Year
- AMC $8.13
- ZYME $99.52
- Revenue Next Year
- AMC $6.66
- ZYME N/A
- P/E Ratio
- AMC N/A
- ZYME N/A
- Revenue Growth
- AMC 9.42
- ZYME 95.94
- 52 Week Low
- AMC $2.45
- ZYME $9.03
- 52 Week High
- AMC $5.56
- ZYME $19.98
- Technical
- Relative Strength Index (RSI)
- AMC 37.83
- ZYME 63.19
- Support Level
- AMC $2.49
- ZYME $17.27
- Resistance Level
- AMC $2.92
- ZYME $19.98
- Average True Range (ATR)
- AMC 0.12
- ZYME 0.73
- MACD
- AMC -0.02
- ZYME 0.01
- Stochastic Oscillator
- AMC 20.21
- ZYME 58.30
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.